Molecular Insight Sets IPO Terms

Molecular Insight Pharmaceuticals Inc., a Cambridge, Mass.-based developer of molecular imaging pharmaceuticals and targeted radio-therapeutics, has set its proposed IPO terms to five million common shares being offered at between $14 and $16 per share. It plans to trade on the Nasdaq under ticker symbol MIPI, with RBC Capital Markets and Jefferies & Co. serving as co-lead underwriters. The company has raised over $35 million in VC funding from firms like Cerberus Capital Management and Siemens Venture Capital. www.molecularinsight.com